Article

A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer

Cancer Chemotherapy and Pharmacology (Impact Factor: 2.57). 09/2008; 62(5):763-768. DOI: 10.1007/s00280-007-0661-y

ABSTRACT PurposeThis open-label, multicenter phase II study was conducted to investigate the efficacy and safety of capecitabine plus gemcitabine
combination chemotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.

Patients and methodsWe enrolled 63 patients who received capecitabine 830mg/m2 orally twice daily on days 1–21 plus gemcitabine 1000mg/m2 as a 30-min infusion on days 1, 8 and 15 every 4weeks for up to six cycles.

ResultsA total of 14 patients had partial responses giving an overall response rate of 22% (95% confidence interval [CI] 13–34%)
in the intent-to-treat population. The median time to progression and overall survival were 3.9months (95% CI 3.5–5.7) and
7.5months (95% CI 5.0–10.0), respectively, and 1-year survival rate was 27.1% in the intent-to-treat population. Capecitabine
plus gemcitabine was well tolerated. Grade 3 hematological adverse events were neutropenia (21%) and thrombocytopenia (2%);
the only grade 4 hematological events were anemia (2%) and neutropenia (6%). Non-hematological adverse events were mainly
gastrointestinal events and hand–foot syndrome, which affected 16% of patients. Grade 3/4 non-hematological events were infrequent.

ConclusionThe combination of capecitabine plus gemcitabine appears to be active and well tolerated as first-line treatment in patients
with advanced/metastatic pancreatic cancer.

0 Followers
 · 
78 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd. #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.
    Hospital pharmacy 02/2014; 49(2):127-33. DOI:10.1310/hpj4902-127
  • [Show abstract] [Hide abstract]
    ABSTRACT: The structural and electronic properties of ellagic acid (EA), its derivatives and metabolites are investigated at the density functional level. Analysis shows that the compounds display estrogenic activity due to the type and number of biophores in their molecular structures. This study explores bond dissociation enthalpy, adiabatic ionization potential, proton dissociation enthalpy, proton affinity, and electron transfer enthalpy in order to understand the antioxidant properties of EA. From the thermodynamic point of view, the transfer mechanism of the hydrogen atom is the most important in free radical scavenging progress. A comparison of BDE values for different types of antioxidants shows that EA and its derivatives can be classified as potent natural antioxidants.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this work, we evaluated combinations of doxorubicin with INNO-206, a (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH) that is currently undergoing two phase II clinical trials, in a primarily chemoresistant tumor indication, i.e. pancreatic cancer. Thus, we compared the antitumor efficacy and tolerability of the following weekly intravenous treatments in the MIA PaCa-2 xenograft model: 3×6mg doxorubicin (MTD), 3×24mg/kg DOXO-EMCH (doxorubicin equivalents, MTD), 3×3mg/kg doxorubicin followed 6h later by 3×12mg/kg DOXO-EMCH, and 3×12mg/kg DOXO-EMCH followed 6h later by 3×3mg/kg doxorubicin. Whereas therapy with doxorubicin only produced a moderate tumor inhibition, all other therapy arms induced complete and partial remissions up to the end of the experiment on day 43. Although the total amount of doxorubicin equivalents is 72mg/kg when DOXO-EMCH is administered alone, but only 45mg/kg doxorubicin equivalents are administered in the combination regimens, the antitumor efficacy in all treated groups was essentially identical, a surprising finding of this study. However, there were significant differences in the tolerability as assessed by the body weight changes: whereas therapy at the MTD of DOXO-EMCH (3×24mg/kg) produced a body weight loss of-16% including one death, therapy with 3×12mg/kg DOXO-EMCH followed 6h later by 3×3mg/kg doxorubicin produced-7% body weight loss, and 3×3mg/kg doxorubicin followed 6h later by 3×12mg/kg DOXO-EMCH produced a body weight gain of +2% as a clear indication of minimal systemic toxicity. In addition, cell culture experiments revealed additive to synergistic effects when MIA PaCa-2 cells were exposed to doxorubicin followed 6h later to exposure of the albumin-bound form of DOXO-EMCH spanning a ratio of 1:5 to 5:1 (analyzed for synergistic, additive or antagonistic effects using the software program CalcuSyn®). This animal study demonstrates that the time-dependent schedule of an albumin-binding prodrug and a free drug has a critical influence on the overall tolerability. A combination of doxorubicin and DOXO-EMCH is currently being investigated in a phase Ib study.
    International Journal of Pharmaceutics 11/2012; 441(1-2). DOI:10.1016/j.ijpharm.2012.11.003 · 3.79 Impact Factor